Abstracts tagged "Gout and outcome measures"

Abstract Number: 2005 • 2013 ACR/ARHP Annual Meeting
Predictors Of Outcomes In Tophaceous Gout- Results From a Prospective Cohort At The Veterans Affairs
Puja Khanna^1,2, Cleopatra Aquino-Beaton³, Jasvinder A. Singh⁴, Erin Duffy⁵, David Elashoff⁶ and Dinesh Khanna⁷, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Rheumatology, Ann Arbor VA, Ann Arbor, MI, ³Rheumatology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ⁴Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁵Medicine, University of California Los Angeles, Los Angeles, CA, ⁶Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁷University of Michigan Health System, Ann Arbor, MI
Background/Purpose: Tophaceous gout is a chronic inflammatory arthritis that causes debilitating acute attacks and associated with exponential resource utilization. Our objective was to define predictors…
Abstract Number: 148 • 2012 ACR/ARHP Annual Meeting
Towards a Preliminary Definition of Remission From Gout
William Taylor¹, Nicola Dalbeth², Jasvinder A. Singh³, Kenneth G. Saag⁴ and H. R. Schumacher⁵, ¹University of Otago, Wellington, New Zealand, ²Medicine, University of Auckland, Auckland, New Zealand, ³Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁴Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ⁵Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA
Background/Purpose: There is currently no agreed criterion for remission in chronic gout. The aim of this study was to develop a preliminary definition for remission…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].